1. The current place of progestins in the treatment of endometriosis
- Author
-
Karl-Werner Schweppe
- Subjects
Drug ,medicine.drug_class ,media_common.quotation_subject ,Endometriosis ,Pharmacology ,Bioinformatics ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Maternity and Midwifery ,Medicine ,Potency ,Sex organ ,030212 general & internal medicine ,media_common ,030219 obstetrics & reproductive medicine ,Medical treatment ,business.industry ,Obstetrics and Gynecology ,medicine.disease ,3. Good health ,Reproductive Medicine ,Tolerability ,Estrogen ,Pediatrics, Perinatology and Child Health ,business - Abstract
Endometriosis is a chronic disease that has a variety of symptoms and reduces quality of life in affected women. The patient complaints require surgical treatment, medical treatment, or both. Often long-term or repeated medication is necessary. Therefore, not only the efficacy, but also the tolerability and costs of a drug are relevant. Oral progestins with or without an estrogen component have been described as being effective in the treatment of endometriosis. A number of different substances have been tried; derivatives of natural progesterone or of C17-OH-progesterone, or derivatives of C19-nortestosterone. Their common characteristic is the secretory transformation of estrogen-primed uterine endometrium for which different doses are necessary because of the different biological activities of these derivatives. They differ with respect to their profile and potency of action on the hypothalamic–pituitary axis, metabolic processes, breast tissue and genital organs. They are similarly effective in the tr...
- Published
- 2012
- Full Text
- View/download PDF